Author

S. A. Johnsen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

R. L. Kosinsky· 2 shared A. Pejkovska· 1 shared A. Scarpa· 1 shared B. Erbil· 1 shared B. Horsthemke· 1 shared B. Sitek· 1 shared C. Schroeder· 1 shared D. B. Lipka· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

R. L. Kosinsky

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

L. K. Godfrey, J. Forster, S.-T. Liffers, C. Schroeder, J. Koester, L. Henschel, K. U. Ludwig, M. Trajkovic-Arsic, D. Behrens, A. Scarpa, R. T. Lawlor, K. E. Witzke, B. Sitek, S. A. Johnsen, S. Rahmann, , J. T. Siveke

This study identifies adaptive DNA methylation changes and clonal expansion as mechanisms of resistance to MEKi in PDAC, showing reversibility upon drug withdrawal.

bioRxiv · May 20, 2022 · PreprintCancer Biology

Loss of Usp22 enhances histone H2B monoubiquitination and stimulates intracellular and systemic interferon immunity

N. Dietlein, X. Wang, E. Rodriguez Correa, B. Erbil, D. B. Lipka, Y. Begus-Nahrmann, R. L. Kosinsky, S. A. Johnsen, T. H. Winkler, H.-R. Rodewald

The paper shows that loss of Usp22 increases H2Bub1 levels, leading to enhanced ISG expression and IFN immunity in mice.

bioRxiv · Apr 9, 2021 · PreprintImmunology

RNF40-dependent epigenetic regulation of actin cytoskeletal dynamics is required for HER2-driven mammary tumorigenesis

F. Wegwitz, E. Prokakis, A. Pejkovska, R. L. Kosinsky, M. Glatzel, K. Pantel, H. Wikman, S. A. Johnsen

This study identifies RNF40's role in HER2-positive breast cancer by showing its requirement for H2B monoubiquitination, which regulates actin dynamics and tumor growth.

bioRxiv · Feb 24, 2020Cancer Biology